Learning from others' mistakes, low-profile microRNA biotech looks to prove itself in the clinic
The same year that Alnylam and Isis — long before it was renamed Ionis — spun out their microRNA research into Regulus Therapeutics, an oncology-focused VC in Europe quietly birthed its own biotech startup to pursue its own collection of these molecules.
Regulus, which went public in 2012, has seen its ups and downs over the ensuing 13 years. Utrecht, Netherlands-based InteRNA, though, says it’s just getting started with an extended Series B round totalling $22.4 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
